1. Scrip

India Steps Up Scrutiny After Chinese API Prices, Military Tensions Rise

Drug Shortages Not Expected In The Short-Term

 
• By Vibha Ravi

A recent military skirmish with China and a 35-40% average increase in prices of drug raw materials has seen India step up scrutiny of imports from the country. While the industry is seeking a hike in domestic formulations prices, product shortages are not expected in the short term.

China and India flags
Political Posturing Or Business Troubles? • Source: Shutterstock

India’s customs department recently stepped up its scrutiny of pharmaceutical raw materials imported from China after several, including those for drugs such as paracetamol and antibiotics, saw 35-40% average price increases, and a military face-off with China led to calls for the rejection of goods manufactured in the country.

After a hand-to-hand skirmish between Indian and Chinese soldiers on 15 June led to fatalities, the Indian government banned 59 Chinese-owned apps, including TikTok and WeChat

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.